Blood Pressure Reduction and Decongestion diuresis. 11, 12 Therefore, the primary goal of this study was to investigate whether either reduction in blood pressure or the initiation/uptitration of neurohormonal antagonists would negatively influence metrics of decongestion, either directly or indirectly as a precipitant of a reduction in blood pressure.
Methods
We reviewed consecutive admissions to the hospital of the University of Pennsylvania with a primary discharge diagnosis of congestive HF admitted to the noninterventional cardiology and internal medicine services between 2004 and 2009 (n=656) . The details of assembly of this cohort, including a consort diagram, have been previously published. 13 Inclusion required a B-type natriuretic peptide level of >100 pg/mL within 24 hours of admission, receipt of intravenous loop diuretics, and availability of data on fluid intake and output during the hospitalization. One additional patient was excluded as day of discharge systolic blood pressure (SBP) was not recorded. Patients were selected who had a length of stay of ≥3 and <14 days. Patients requiring renal replacement therapy were excluded. In the event of multiple hospitalizations for a single patient, only the first admission that satisfied the inclusion and exclusion criteria was used. The Social Security Death Index was used to determine all-cause mortality status. 14 All-cause mortality was ascertained 2.5 years after discharge of the last patient in the cohort.
Focus of this analysis was on relative change in SBP as our previous work identified SBP to be the most important determinant of change in renal function. 4 Admission SBP was calculated as the mean of the first 3 values recorded in the chart and discharge SBP from the last 3. SBP reduction was dichotomized about the median to define the presence or absence of significant SBP reduction. 4 Estimated glomerular filtration rate (GFR) was calculated using the 4-variable Modification in Diet for Renal Disease formula. 15 WRF was defined as ≥20% decrease and improvement in renal function as a ≥20% improvement in estimated GFR to account for the nonlinear relationship between renal function and serum creatinine. 16 Comparisons in estimated GFR were from admission to discharge. Hemoconcentration was defined as an increase in both hemoglobin and hematocrit at discharge when compared with admission values. 17 Proportional pulse pressure was calculated as the ratio of the difference between systolic and diastolic blood pressures to SBP at admission and discharge.
Loop diuretic doses were converted to furosemide equivalents with 1 mg bumetanide=20 mg torsemide=80 mg furosemide for oral doses and 1 mg bumetanide=20 mg torsemide=40 mg furosemide for intravenous doses. 18, 19 Diuretic efficiency (DE) was calculated by dividing the cumulative net fluid output during hospitalization by the cumulative intravenous loop diuretic dose (expressed as per 40 mg IV furosemide equivalents) over the hospitalization. 13 Uptitration of neurohormonal antagonists was considered to have occurred if the dose of either ACE/ angiotensin receptor blocker (ARB) or β-blocker was greater at any time during the hospitalization than the dose before admission.
This study was approved or determined to qualify as exempt by the Institutional Review Boards of the Hospital of the University of Pennsylvania and Yale University.
Statistical Analysis
Values are reported as mean±SD, median (quartile 1 to quartile 3), or percentage. Student t test, Wilcoxon signed-rank test, or Kruskal-Wallis test was used to compare continuous variables between groups. Categorical variables were compared using the χ 2 test. The independent relationships between blood pressure reduction, WRF, DE, and medication initiation/titration were determined using logistic regression. Baseline variables with a univariate association with any of the above variables P<0.2 and with <10% missing values were entered into the model. These included age, sex, race, hypertension, diabetes mellitus, ischemic HF pathogenesis, ejection fraction, heart rate, SBP, edema, blood urea nitrogen, hemoglobin, B-type natriuretic peptide, serum sodium, estimated GFR, and baseline medication use. Models were built using backward elimination such that covariates with an association with mortality at P<0.2 were retained. 20 Cox proportional hazards models were used to evaluate time-to-event associations with all-cause mortality. Logistic regression using fractional polynomials of discharge SBP on the outcomes of low DE and WRF was performed. Plots of the odds of outcome over discharge SBP were then created to visually assess nonlinear relationships. A 2-sided P value of <0.05 was considered significant for all study analysis. Statistical analysis was performed with IBM SPSS Statistics version 21.0 (IBM Corp, Armonk, NY) and Stata 13.1 (StataCorp, College Station, TX).
Results
Baseline characteristics of the cohort are presented in Table 1 . Overall, 77.6% of patients had a discharge SBP lower than the admission value, which translated into a mean absolute SBP reduction of 14.4±19.4 mm Hg. The median relative reduction in SBP was 9.9% (1.4%-18.2%), and patients with an SBP reduction larger than this value were classified as having had significant SBP reduction. Patients with significant SBP reduction were more commonly black, were more commonly female, had a lower prevalence of diabetes mellitus, and had less ischemic HF (Table 1 ). SBP and heart rate were higher, and edema was less prevalent at the time of admission in patients with SBP reduction ( Table 1 ). Baseline parameters of renal function tended to be better in patients who experienced SBP reduction ( Table 1 ). Medications were similar with the exception of the loop diuretic dose, which tended to be lower in patients who experienced SBP reduction (Table 1) . SBP reduction was associated with improved survival on univariate analysis (hazard ratio, 0.79; 95% confidence interval [CI], 0.64-0.97; P=0.03); however, this relationship was no longer present after adjustment for baseline SBP (P=0.40).
SBP Reduction and Renal Function
Similar to previous reports, SBP reduction was associated with WRF (odds ratio [OR], 1.9; 95% CI, 1.2-2.9; P=0.004; Figure 1 ), and this association remained after adjusting for baseline characteristics, including SBP (OR, 1.8; 95% CI, 1.1-3.0; P=0.01). Furthermore, this relationship did not seem to be driven by aggressive diuresis because after controlling for in-hospital diuretic/treatment-related parameters, such as net fluid loss, total intravenous loop diuretic received, peak loop diuretic given in 24 hours, length of stay, hemoconcentration, DE, and inotrope use, SBP reduction remained strongly linked to WRF (OR, 2.0; 95% CI, 1.3-3.2; P=0.002). Furthermore, the relationship seemed to be primarily driven by the change rather than the absolute level of discharge blood pressure because the risk of WRF was unchanged after adjustment for discharge blood pressure (OR, 1.9; 95% CI, 1.2 -2.9; P=0.004); a trend toward a negative association between reduction in SBP as a continuous parameter and odds for WRF was also observed (Supplementary Figure 1A) . SBP reduction was associated with a lower incidence of improvement in renal function (OR, 0.4; 95% CI, 0.3-0.7; P<0.001), and the odds for WRF compared with improvement in renal function were substantially greater in patients who experienced SBP reduction (OR, 3.4; 95% CI, 2.0-6.0; P<0.001). In sensitivity analysis examining the changes in proportional pulse pressure rather than SBP, we were unable to identify an association with the risk of either WRF (P=0.96) or low DE (P=0.84). Figure 1 ), and this lack of association remained after adjusting for baseline characteristics (OR, 0.9; 95% CI, 0.3-1.3; P=0.47) and evaluation of this relationship using SBP reduction as a continuous parameter (Supplementary Figure 1B) . SBP reduction did not affect other metrics of diuresis and decongestion, such as total and daily net urine output, loop diuretic dose, use of adjuvant thiazides, hemoconcentration, percent of loop diuretic given intravenously, and length of stay ( Figure 1 and Table 2 ).
SBP Reduction and Diuresis

Importance and Interactions With Discharge SBP
The average SBP at the time of discharge was 117±22 mm Hg. Overall, there was no linear interaction between the risk of WRF (P interaction=0.78) and low DE (P interaction=0.26) with discharge SBP. However, this lack of interaction was likely driven by the fact that there were few patients with severe hypotension as only 67 (10%) patients had an SBP of ≤90 mm Hg, 39 (6%) ≤85 mm Hg, and 20 (3.0%) ≤80 mm Hg. Across the majority of the spectrum of discharge blood pressure, the risk of WRF and low DE was flat (Figure 2A ). However, below an SBP of 85 mm Hg, a trend toward increased WRF (OR, 1.6; P=0.26) and low DE (OR, 1.6; P=0.14) emerged. A statistically significant increase in WRF and low Figure 2B ).
Titration of Neurohormonal Antagonists
Titration or initiation of neurohormonal antagonists was common with 48.7% of the population starting or uptitrating ACE/ARB, 39.0% β-blockade, 22.9% both medications, and 65.1% one of the 2 classes of medication during hospitalization. Among patients who initiated ACE inhibitor therapy during hospitalization, the median starting dose was 5 mg (5-10 mg) of lisinopril equivalents, whereas the median uptitration was by 10 mg (5-20 mg). Among patients who initiated ARB therapy during hospitalization, the median starting dose was 37.5 mg (25-50 mg) of losartan equivalents, whereas the median uptitration was by 50 mg (25-50 mg). Newly starting or increasing the dosage of ACE/ARB or β-blocker was associated with a greater incidence of SBP reduction on univariable analysis (Table 3 ). However, the magnitude of additional blood pressure reduction was modest (ACE/ARB, 4.7 mm Hg; β-blocker, 5.6 mm Hg; both, 5.4 mm Hg; P<0.003 for all), and after adjustment for baseline characteristics, there was no longer a significant relationship between initiation or uptitration of these medications and SBP reduction (Table 3 ). There was no relationship between initiation or uptitration of ACE/ARB or β-blockers with WRF both on univariable and multivariable analyses (Table 3) . Similarly, the incidence of improvement in renal function versus WRF was similar between patients who did or did not start/uptitrate ACE/ARB (OR, 1.0; 95% CI, 0.6-1.7; P=0.92). Interestingly, there was a strong relationship between initiation or uptitration of ACE/ARB and improved DE ( Table 3 ). Median DE was significantly higher in patients with initiation/uptitration of ACE/ARB compared with those on stable doses (605 mL/40 mg furosemide [251-1245] versus 399 mL/40 mg furosemide [176-853]; P=0.001). This relationship persisted after extensive adjustment for baseline characteristics, including medication use (Table 3 ), in addition to in-hospital parameters, such as length of stay, inotrope use, hemoconcentration, SBP reduction, and WRF (OR, 1.5; 95% CI, 1.0-2.1; P=0.04). Initiation or uptitration of β-blockers did not significantly influence DE (Table 3 ). Furthermore, initiation of mineralocorticoid receptor antagonist therapy (n=73) was not associated with increased odds for WRF (P=0.52) or low DE (P=0.90). The rate of a discharge SBP of <80 mm Hg, 85 mm Hg, or 90 mm Hg was not significantly changed with in-hospital titration of either ACE/ARB or β-blocker therapy (P≥0.19 for all comparisons), and the odds for high DE with new start or uptitration of ACE/ARB were unaffected by adjustment for discharge SBP (OR, 1.7; 95% CI, 1.3-2.4; P<0.001).
Discussion
The primary findings of the current analysis are that (1) despite the strong relationship between blood pressure reduction and WRF, blood pressure reduction was not negatively associated with a wide range of metrics of diuresis and decongestion. (2) Initiation or uptitration of neurohormonal antagonists, such as ACE/ARB or β-blockade, did not seem to increase the rate of Significant systolic blood pressure reduction was defined as relative decline in blood pressure from admission to discharge greater than the median value (>9.9% reduction). IV indicates intravenous. 4) The absolute level of blood pressure was only linked to a higher rate of WRF or worse diuresis in patients with moderate to severe hypotension (SBP <80 mmHg). Although these results are observational and causality cannot be concluded, they do provide reassurance that current guideline recommendations to use ADHF admission as an opportunity to titrate potentially life-saving chronic oral therapy are not antagonistic to the short-term goal of decongestion. The observed differences between patients with and without SBP reduction were similar to findings previously reported from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial, where notable differences in baseline characteristics between patients with and without SBP reduction included better metrics of renal function and higher blood pressure. 4 The observation that reduction in blood pressure is strongly associated with a higher rate of WRF has been reported in several populations. [4] [5] [6] [7] Notably, changes in blood pressure have been shown to be significantly more important than change in invasively determined cardiac index, right atrial pressure, and pulmonary capillary wedge pressure. 5 However, beyond these well-documented effects on glomerular filtration, little is known about the consequences of reducing blood pressure on other domains of renal function, such as sodium and water handling. Diuretic therapy represents the mainstay of therapy for decongestion in ADHF, and thus, the kidney serves as the conduit for volume removal in the majority of patients. Therefore, factors that affect kidney function could in theory compromise successful decongestion. However, in the current analysis, we found that across a diverse spectrum of markers of diuresis and decongestion, there was no negative effect of reduction in blood pressure. These findings add to a growing literature suggesting that treatment-induced changes in serum creatinine of small to moderate magnitude may have limited clinical importance. 21 Among this literature is the Diuretic Strategies in Patients with Acute Decompensated Heart Failure (DOSE) trial, which found that use of high-dose compared with low-dose loop diuretics did not result in worsened outcomes despite a significantly increased rate of WRF. 22 Another important finding of the current analysis was that initiating or increasing the dose of neurohormonal antagonists, Relationship between discharge blood pressure and worsening renal function (A) and low diuretic efficiency (B). Red line represents the odds for either worsening renal function (WRF) or low diuretic efficiency (DE) as a function of discharge systolic blood pressure with a reference blood pressure of 117 mm Hg (the mean value in the population). The cut point of a discharge systolic blood pressure of 80 mm Hg, below which odds of both WRF and low DE were significantly increased, is marked in gray. Systolic blood pressure reduction defined as relative decline in blood pressure from admission to discharge greater than the median value (>9.9% reduction). High diuretic efficiency defined as a value greater than the median (480 mL/40 mg). ACE indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CI, confidence interval; and OR, odds ratio.
in the context of careful selection of patients by the treating physician, did not lead to a detectable diminution in diuresis and decongestion. Notably, a new start or uptitration of ACE/ARB or β-blockade occurred in over half of the population. Although blood pressure was reduced to a greater extent in these patients, the absolute change in blood pressure was modest and the signal largely eliminated with adjustment for baseline confounders. This likely contributed to the absence of a statistically significant increase in the rate of WRF with initiation or uptitration of neurohormonal antagonists. However, many of the mechanisms by which hemodynamic perturbations and diuretic therapy lead to WRF and diuretic resistance are mediated via neurohormonal activation. 11, 12, 23 Although renin-angiotensin-aldosterone system inhibitors are often considered to have detrimental renal effects, there are potent positive direct renal effects. Specifically, inhibition of the renin-angiotensin-aldosterone system can lead to attenuation of renal angiotensin II-induced sodium reabsorption and increased renal blood flow, which may enhance diuresis or preserve GFR. 23, 24 Illustrating this point, in an elegant study by Chen et al, 11 administration of losartan simultaneously with a dose of furosemide resulted in preservation of GFR, renal plasma flow, and improved sodium excretion compared with furosemide administered alone. As a result, it is plausible that the improved DE and the absence of an increase in WRF with initiation/titration of ACE inhibitors or ARB in the current analysis were in part driven by direct positive renal neurohormonal and hemodynamic effects of the medications.
The finding of a J-shaped relationship between both WRF and DE with the absolute level of discharge blood pressure provides an important caveat in interpreting the above results. As the absolute level of discharge blood pressure approached 80 mm Hg, the odds for both WRF and low DE sharply increased. Reassuringly, this was a relatively uncommon scenario as only 10% of the population had a discharge blood pressure of <90 mm Hg and only 3% <80 mm Hg, and over the remainder of the spectrum above this range, discharge blood pressure was unrelated to both WRF and DE. However, these findings do highlight the common sense fact that caution should be exercised in starting or titrating antihypertensive therapies, such as neurohormonal antagonists, when significant hypotension is present.
Limitations
Given the post hoc retrospective nature of this analysis, uncontrolled confounding cannot be excluded and causality is impossible to conclude. Importantly, patients in this study were not randomized to a decrease in blood pressure or titration of neurohormonal antagonists. Rather, physicians who were not blinded to blood pressure, renal function, or metrics of diuresis made clinical decisions in part based on the aforementioned parameters. As a result, the observations presented here are in the context of the clinical assessment and patient selection of a treating physician who felt it was safe/advantageous to carry out the treatment plan, such as titration of the ACE inhibitor. Therefore, it should not be assumed that titration of neurohormonal antagonists or reduction in blood pressure in unselected patients will produce the same results. Furthermore, net fluid balance is known to be difficult to track accurately even in ideal clinical conditions, and therefore, point estimates resulting from this metric should be viewed in context of this limitation. 25 Although an average of 3 admission and 3 discharge values was taken to calculate change in blood pressure, blood pressure may have been labile throughout the hospitalization in many patients. As a result, the effect of transient changes in blood pressure on renal function and diuresis remains unknown. Furthermore, the exact time of each blood pressure measurement was not recorded; as a result, we are unable to exclude confounding by the length of time over which average admission SBP and discharge SBP were determined. In addition, transient worsening in renal function can result specifically from coadministration of multiple drugs (such as in the morning), and confounding because of this effect cannot be excluded.
Conclusions
Reduction in blood pressure during the treatment of ADHF is strongly associated with WRF, but this was not associated with a worsening of diuresis. Titration of neurohormonal antagonists is associated with a modest decrease in blood pressure; however, this did not translate into a significant increase in the rate of WRF, and DE was actually improved. These results provide reassurance that the guideline-recommended practice of titrating chronic oral medication during the treatment of ADHF, in appropriately selected patients, is likely not antagonistic to the short-term goal of decongestion. Additional research is warranted to investigate whether routine uptitration of ACE/ARB during the treatment of ADHF can be recommended to improve diuresis.
